C12Y 207/07001
Nicotinamide-nucleotide adenylyltransferase
Official title: Nicotinamide-nucleotide adenylyltransferase (2.7.7.1)
C12Y207/07001 (Nicotinamide-nucleotide adenylyltransferase) appears on 9 US grants and 23 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 23
- Assignees
- 15
- Inventors
- 45
- Latest grant
- 24 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 3 |
| 2019 | 0 | 4 |
| 2020 | 2 | 1 |
| 2021 | 0 | 3 |
| 2022 | 2 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 2 | 3 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment and prevention of ocular neurodegenerative disorder24 Jun 2025US 12,336,986 B2The Jackson Laboratory
- Gene therapy for NMNAT1-associated retinal degeneration25 Mar 2025US 12,257,320 B2Massachusetts Eye and Ear Infirmary
- Genetically engineered bacteria, its construction method and its application in producing NAD+ method24 Dec 2024US 12,173,338 B2Hefei Knature Bio-Pharm Co., Ltd.
- 4-thioribose NAD analogues and methods of synthesizing and using the same5 Dec 2023US 11,834,470 B2University of Southern California
- Treatment and prevention of ocular neurodegenerative disorder19 Jul 2022US 11,389,439 B2The Jackson Laboratory
- Nicotinamide adenine dinucleotide devices and compositions and methods for making the same27 Aug 2026US 2026/0250695 A1Bio Capital Holdings, LLC
- Protein devices and compositions and methods for making the same30 Jul 2026US 2026/0218214 A1Bio Capital Holdings, LLC
- Treatment and prevention of ocular neurodegenerative disorder18 Dec 2025US 2025/0381177 A1The Jackson Laboratory
- Gene Therapy for NMNAT1-Associated Retinal Degeneration28 Aug 2025US 2025/0269068 A1Massachusetts Eye and Ear Infirmary
- Methods for the treatment of hrd cancer and brca-associated cancer16 Jan 2025US 2025/0019708 A1Institut Curie
Most cited
By later US patents
- Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity4US 10,603,334 B2Newsouth Innovation Pty Limited · 2020
- Methods and compositions for nucleoside triphosphate and ribonucleic acid production3US 10,858,385 B2GreenLight Biosciences, Inc. · 2020
- NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation3US 9,877,981 B2NewSouth Innovations Pty Limited · 2018
- Treatment and prevention of ocular neurodegenerative disorder1US 11,389,439 B2The Jackson Laboratory · 2022